AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
ABBVIE INC.
XNYS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG0025Y4RZ3
285.64▲ 0.45 (0.16%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
285.19
Day's Range
282.30 – 286.77
52-Week Range
190.75 – 291.40
Volume
4.6M
Avg Volume
4.6M
Share Statistics
Shares Outstanding
Employees
57.0K
Exchange
XNYS
Listed
2012-12-10
Share count as of July 27, 2026

ABBVIE INC. (ABBV) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about ABBVIE INC. (ABBV)
What is ABBVIE INC.'s Market Cap?
ABBVIE INC.'s Market Cap is $504.8B, based on as-reported figures from SEC (XBRL) filings.
What is ABBVIE INC.'s Enterprise Value?
ABBVIE INC.'s Enterprise Value is $569.0B, based on as-reported figures from SEC (XBRL) filings.
What is ABBVIE INC.'s Trailing P/E?
ABBVIE INC.'s Trailing P/E is 80.0×, based on as-reported figures from SEC (XBRL) filings.
What is ABBVIE INC.'s Price / Sales?
ABBVIE INC.'s Price / Sales is 7.8×, based on as-reported figures from SEC (XBRL) filings.
What is ABBVIE INC.'s EV / Revenue?
ABBVIE INC.'s EV / Revenue is 8.8×, based on as-reported figures from SEC (XBRL) filings.
What is ABBVIE INC.'s EV / EBITDA?
ABBVIE INC.'s EV / EBITDA is 23.0×, based on as-reported figures from SEC (XBRL) filings.
What is ABBVIE INC.'s Revenue (TTM)?
ABBVIE INC.'s Revenue (TTM) is $64.4B, based on as-reported figures from SEC (XBRL) filings.
What is ABBVIE INC.'s Net Income (TTM)?
ABBVIE INC.'s Net Income (TTM) is $6.3B, based on as-reported figures from SEC (XBRL) filings.
What is ABBVIE INC.'s EBITDA?
ABBVIE INC.'s EBITDA is $24.7B, based on as-reported figures from SEC (XBRL) filings.
What is ABBVIE INC.'s Diluted EPS (TTM)?
ABBVIE INC.'s Diluted EPS (TTM) is 3.57, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ABBVAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Net revenues
YoY growth+10.2%+12.4%+10.0%+9.1%
Cost of products sold
Selling, general and administrative
Research and development
Acquired IPR&D and milestones
Other operating income—
Total operating costs and expenses
% of revenue62.1%73.4%72.7%87.9%
Operating earnings
% of revenue37.9%26.6%27.3%12.1%
Interest expense, net
Other expense, net
Earnings before income tax expense
Income tax expense
Net earnings
% of revenue21.3%4.6%10.9%1.2%
Net earnings attributable to noncontrolling interest
Net earnings attributable to AbbVie Inc.
% of revenue21.3%4.6%10.9%1.2%
Per share data
Basic earnings per share (in dollars per share)
Diluted earnings per share (in dollars per share)